Stocktoria
enVVeno Medical Corp NVNO
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2018-05-31
enVVeno Medical Corp financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $31,243 | $186,552 | $422,111 |
| Gross profit | — | — | — | — | — | — | — | $186,552 | $2,452 |
| R&D expense | $10.0M | $12.2M | $13.6M | $9.9M | $5.7M | $4.3M | $2.2M | $1.2M | $649,736 |
| SG&A expense | $10.9M | $11.6M | $11.7M | $15.0M | $11.2M | $4.9M | $4.9M | $6.5M | $5.5M |
| Operating income | -$20.9M | -$23.8M | -$25.2M | -$24.9M | -$16.9M | -$9.1M | -$7.7M | -$7.9M | -$6.1M |
| Net income | -$19.5M | -$21.8M | -$23.5M | -$24.7M | -$16.5M | -$9.1M | -$7.6M | -$13.0M | -$7.8M |
| EPS (diluted) | $-33.06 | $-44.53 | $-1.91 | $-2.20 | — | — | — | — | — |
| Operating cash flow | -$15.6M | -$16.8M | -$18.9M | -$15.6M | -$11.8M | -$7.7M | -$5.9M | -$6.4M | -$4.2M |
| Free cash flow | -$15.6M | -$16.9M | -$18.9M | -$15.7M | -$12.2M | -$7.9M | -$6.3M | -$6.4M | -$4.2M |
| Cash & equivalents | $3.1M | $1.8M | $3.6M | $4.6M | $54.7M | $9.3M | $1.3M | $2.7M | $77,688 |
| Total assets | $29.6M | $45.0M | $48.6M | $41.7M | $57.7M | $10.5M | $3.4M | $3.6M | $2.2M |
| Total liabilities | $2.4M | $2.8M | $2.4M | $2.9M | $3.3M | $3.4M | $2.4M | $1.5M | $8.2M |
| Shareholders' equity | $27.1M | $42.2M | $46.2M | $38.7M | $54.4M | $7.1M | $989,940 | $2.0M | -$11.1M |
Growth · year-over-year · Revenue CAGR -72.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | -83.3% | -55.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.